ATE311865T1 - Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit - Google Patents

Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit

Info

Publication number
ATE311865T1
ATE311865T1 AT98908904T AT98908904T ATE311865T1 AT E311865 T1 ATE311865 T1 AT E311865T1 AT 98908904 T AT98908904 T AT 98908904T AT 98908904 T AT98908904 T AT 98908904T AT E311865 T1 ATE311865 T1 AT E311865T1
Authority
AT
Austria
Prior art keywords
disease
enantiomeric
inflammatory
steroidal anti
prevent alzheimer
Prior art date
Application number
AT98908904T
Other languages
German (de)
English (en)
Inventor
William J Wechter
John D Mccracken
Original Assignee
Univ Loma Linda Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/814,490 external-priority patent/US6160018A/en
Application filed by Univ Loma Linda Med filed Critical Univ Loma Linda Med
Application granted granted Critical
Publication of ATE311865T1 publication Critical patent/ATE311865T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT98908904T 1997-03-10 1998-03-04 Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit ATE311865T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/814,490 US6160018A (en) 1995-03-13 1997-03-10 Prophylactic composition and method for alzheimer's Disease
PCT/US1998/004176 WO1998040061A1 (en) 1997-03-10 1998-03-04 Use of r-nsaid's for the prevention of alzheimer's disease

Publications (1)

Publication Number Publication Date
ATE311865T1 true ATE311865T1 (de) 2005-12-15

Family

ID=25215202

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98908904T ATE311865T1 (de) 1997-03-10 1998-03-04 Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit
AT05026505T ATE446748T1 (de) 1997-03-10 1998-03-04 Verwendung von r-carprofen zur vorbeugung der alzheimerschen krankheit

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05026505T ATE446748T1 (de) 1997-03-10 1998-03-04 Verwendung von r-carprofen zur vorbeugung der alzheimerschen krankheit

Country Status (9)

Country Link
EP (2) EP1642575B1 (cg-RX-API-DMAC7.html)
JP (1) JP2001514655A (cg-RX-API-DMAC7.html)
AT (2) ATE311865T1 (cg-RX-API-DMAC7.html)
AU (1) AU6682298A (cg-RX-API-DMAC7.html)
CA (1) CA2283255C (cg-RX-API-DMAC7.html)
DE (2) DE69841267D1 (cg-RX-API-DMAC7.html)
DK (1) DK0966277T3 (cg-RX-API-DMAC7.html)
ES (1) ES2253810T3 (cg-RX-API-DMAC7.html)
WO (1) WO1998040061A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2163986B1 (es) * 1999-07-13 2003-02-16 Menarini Lab Acidos-alfa-arilpropionicos y arilaceticos como inhibidores de la ciclooxigenasa-ii.
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20040127471A1 (en) * 2002-09-17 2004-07-01 Barry Reisberg Methods of treating age associated memory impairment (AAMI), mild cognitive impairment (MCI), and dementias with cell cycle inhibitors
US7074826B2 (en) * 2002-10-07 2006-07-11 Encore Pharmaceuticals, Inc. R-NSAID esters and their use
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
JP2010529101A (ja) 2007-06-04 2010-08-26 テックフィールズ インコーポレイテッド 非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用
CN108191846B (zh) 2008-12-04 2021-08-20 于崇曦 高穿透性组合物及其应用
HK1207562A1 (en) 2012-01-18 2016-02-05 苏州泰飞尔医药有限公司 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
WO2015006489A1 (en) 2013-07-11 2015-01-15 University Of North Texas Health Science Center At Fort Worth Blood-based screen for detecting neurological disease in primary care settings
EP3074525B1 (en) 2013-11-26 2024-06-26 University of North Texas Health Science Center at Fort Worth Personalized medicine approach for treating cognitive loss
JP7412003B2 (ja) 2018-01-18 2024-01-12 ユニバーシティー オブ ノース テキサス ヘルス サイエンス センター アット フォートワース アルツハイマー病に罹患している患者の特定の亜集団を治療するためのnsaid及びドネペジルについてのコンパニオン診断
EP4076424A1 (en) * 2019-12-20 2022-10-26 Basf Se Composition for the treatment of amyloid-beta associated diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
FR2687915B1 (fr) * 1992-02-28 1995-05-05 Rhone Poulenc Rorer Sa Composition pharmaceutique utilisable comme analgesique contenant l'acide (benzoyl-3 phenyl)-2 propionique-(r).
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US6255347B1 (en) * 1996-06-21 2001-07-03 Advanced Research And Technology Institute Methods and compositions comprising R-ibuprofen

Also Published As

Publication number Publication date
WO1998040061A1 (en) 1998-09-17
EP1642575A1 (en) 2006-04-05
CA2283255C (en) 2007-01-02
EP0966277B1 (en) 2005-12-07
DE69832695D1 (de) 2006-01-12
EP1642575B1 (en) 2009-10-28
EP0966277A1 (en) 1999-12-29
CA2283255A1 (en) 1998-09-17
DE69841267D1 (de) 2009-12-10
DK0966277T3 (da) 2006-03-27
ATE446748T1 (de) 2009-11-15
JP2001514655A (ja) 2001-09-11
ES2253810T3 (es) 2006-06-01
DE69832695T2 (de) 2006-09-14
AU6682298A (en) 1998-09-29

Similar Documents

Publication Publication Date Title
ATE446748T1 (de) Verwendung von r-carprofen zur vorbeugung der alzheimerschen krankheit
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
ATE369848T1 (de) Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie
NO20071490L (no) Farmasoytisk aktive isoindolderivater
RU93005246A (ru) Лекарственное средство для лечения болей и воспалений
CA2260145A1 (en) Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
DK1061940T3 (da) Anvendelse af follistatin til fremstilling af et medikament til behandling af muskelrelaterede lidelser
DK0687176T3 (da) Anvendelse af riluzol til behandling af AIDS-relaterede nervesygdomme
ID24487A (id) Senyawa-senyawa benzosikloheptatiofen
EE04491B1 (et) (+)-nortsisapriidi kasutamine
DE69808440D1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
FI885346L (fi) Ergolinderivat, som foerhindrar parkinsons sjukdom.
IT1302243B1 (it) Sintesi dell&#39;1,1,1,3,3-pentafluoropropano.
FR2684543B1 (fr) Ligament artificiel, notamment pour la cheville.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
DK0424156T3 (da) Behandling af hepatobiliær sygdom med 15-ketoprostaglandinforbindelser
FI912622A7 (fi) Farmakologisesti aktiivisia keskushermostoon vaikuttavia yhdisteitä
NO990450L (no) Behandling av sinnslidelser
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
ID20165A (id) Penggunaan asam 2-(3,4-dimetoksisinamoil)aminobenzoat untuk pembuatan obat untuk pengobatan atau pencegahan restenosis
MY117689A (en) A new process for the preparation of 3-n, n-dicycobutylamino-8-fluoro-3, 4-dihydro-2h-1-benzopyran-5-carboxamide
IT1296613B1 (it) Farmaco per la cura dell&#39;ircismo contenente un adrenocorticosteroide.
IT1312060B1 (it) Uso dell&#39;acido alfa lipoico nel trattamento antimetastatico.
OA09301A (fr) &#34;Nouvelle forme galénique orale améliorant la biodisponibilité&#34;.
BR9809286A (pt) Processos para redução de fibrinogênio

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0966277

Country of ref document: EP